Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 7-8/2018

19.02.2018 | main topic

Methadone as anticancer treatment: hype, hope, or hazard?

A series of case reports and a short review of the current literature and recommendations of the societies

verfasst von: Gudrun Kreye, Eva-Katharina Masel, Klaus Hackner, Beate Stich, Friedemann Nauck

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 7-8/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Recently, the use of methadone in cancer patients has increased due to in vitro studies indicating that methadone is capable of inducing cell death. However, thus far there are no relevant clinical studies indicating that the use of methadone can prolong survival in cancer patients. Based on low-quality evidence, methadone is a drug that has similar analgesic benefits to morphine and has a role in the management of cancer pain in adults. Other opioids such as morphine, hydromorphone, and fentanyl are easier to manage but may be more expensive than methadone in many economies. Methadone is an opioid that is only approved for replacement therapy in Austria. Methadone can be used as a second- or third-line agent for severe cancer-related pain, but its use should be restricted to experts. Here we report a series of cases of patients who developed problems when using methadone as an antitumor treatment, with a brief review on the role of methadone as a pain medication and the current lack of value as an anti-tumor therapy. Methadone is not approved or recommended as an anticancer treatment in Austria or Germany. The Austrian Association for Hemato-oncology (OeGHO), the Austrian Association for the Management of Pain (ÖSG), and the Austrian Association for Palliative Care (OPG) do not recommend the use of methadone as an anticancer treatment. Thus, from a medical and ethical point of view, the use of methadone as an antitumor therapy is to be rejected, based on the views of various Austrian (OeGHO, ÖSG, OPG) and German specialists. Unqualified use of methadone by nonexperienced pain therapists is dangerous and must also be rejected.
Literatur
2.
3.
Zurück zum Zitat Radbruch L, Nauck F. Morphin und andere Opioide in der Tumorschmerztherapie. Die Empfehlungen der EAPC. Schmerz. 2002;16:186–93. CrossRefPubMed Radbruch L, Nauck F. Morphin und andere Opioide in der Tumorschmerztherapie. Die Empfehlungen der EAPC. Schmerz. 2002;16:186–93. CrossRefPubMed
4.
Zurück zum Zitat Cherny N, Ripamonti C, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–54. CrossRefPubMed Cherny N, Ripamonti C, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–54. CrossRefPubMed
6.
Zurück zum Zitat Cherny NJ, Chang V, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76(7):1283–93. CrossRefPubMed Cherny NJ, Chang V, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76(7):1283–93. CrossRefPubMed
8.
Zurück zum Zitat Roth HJ. Arzneistoffe. Stuttgart: Deutscher Apotheker Verlag; 2000. Roth HJ. Arzneistoffe. Stuttgart: Deutscher Apotheker Verlag; 2000.
9.
Zurück zum Zitat Kristensen K, Christensen CB, et al. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45–PL50. CrossRefPubMed Kristensen K, Christensen CB, et al. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45–PL50. CrossRefPubMed
10.
Zurück zum Zitat Raynor K, Kong H, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45(2):330–4. PubMed Raynor K, Kong H, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45(2):330–4. PubMed
11.
Zurück zum Zitat Codd EE, Shank RP, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–70. PubMed Codd EE, Shank RP, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther. 1995;274(3):1263–70. PubMed
12.
Zurück zum Zitat Rostami-Hodjegan A, Wolff K, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48(1):43–52. CrossRefPubMedPubMedCentral Rostami-Hodjegan A, Wolff K, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48(1):43–52. CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986;11(2):87–106. CrossRefPubMed Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986;11(2):87–106. CrossRefPubMed
15.
Zurück zum Zitat Fainsinger R, Schoeller T, et al. Methadone in the management of cancer pain: a review. Pain. 1993;52(2):137–47. CrossRefPubMed Fainsinger R, Schoeller T, et al. Methadone in the management of cancer pain: a review. Pain. 1993;52(2):137–47. CrossRefPubMed
16.
Zurück zum Zitat Weschules DJ, et al. Actual and potential drug interactions associated with methadone. Pain Med. 2008;9(3):315–44. CrossRefPubMed Weschules DJ, et al. Actual and potential drug interactions associated with methadone. Pain Med. 2008;9(3):315–44. CrossRefPubMed
17.
Zurück zum Zitat Lotsch J, Skarke C, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983–1013. CrossRefPubMed Lotsch J, Skarke C, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983–1013. CrossRefPubMed
18.
Zurück zum Zitat Lotsch J, Skarke C, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79(1):72–89. CrossRefPubMed Lotsch J, Skarke C, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79(1):72–89. CrossRefPubMed
20.
Zurück zum Zitat Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9(5):595–612. CrossRefPubMed Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9(5):595–612. CrossRefPubMed
21.
Zurück zum Zitat Nauck F, Ostgathe C, et al. A German model for methadone conversion. Am J Hosp Palliat Care. 2001;18(3):200–2. CrossRefPubMed Nauck F, Ostgathe C, et al. A German model for methadone conversion. Am J Hosp Palliat Care. 2001;18(3):200–2. CrossRefPubMed
23.
Zurück zum Zitat Friesen C, Hormann I, et al. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle. 2014;13:1560–70. CrossRefPubMedPubMedCentral Friesen C, Hormann I, et al. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle. 2014;13:1560–70. CrossRefPubMedPubMedCentral
24.
25.
Zurück zum Zitat Bundscherer A, Malsy M, et al. Effects of ropivacaine, bupivacaine and sufentanil in colon and pancreatic cancer cells in vitro. Pharmacol Res. 2015;95–96:126–31. CrossRefPubMed Bundscherer A, Malsy M, et al. Effects of ropivacaine, bupivacaine and sufentanil in colon and pancreatic cancer cells in vitro. Pharmacol Res. 2015;95–96:126–31. CrossRefPubMed
26.
Zurück zum Zitat Harimaya Y, Koizumi K, et al. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187(1–2):121–7. CrossRefPubMed Harimaya Y, Koizumi K, et al. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187(1–2):121–7. CrossRefPubMed
27.
Zurück zum Zitat Malsy M, Gebhardt K, et al. Effects of ketamine, s‑ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesth. 2015;15:111. CrossRef Malsy M, Gebhardt K, et al. Effects of ketamine, s‑ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesth. 2015;15:111. CrossRef
28.
Zurück zum Zitat Sacerdote P, Bianchi M, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000;90:1411–4. CrossRefPubMed Sacerdote P, Bianchi M, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000;90:1411–4. CrossRefPubMed
29.
Zurück zum Zitat Shavit Y, Ben-Eliyahu S, et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation. 2004;1:255–60. CrossRef Shavit Y, Ben-Eliyahu S, et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation. 2004;1:255–60. CrossRef
30.
Zurück zum Zitat Tegeder I, Grosch S, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63:1846–52. PubMed Tegeder I, Grosch S, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63:1846–52. PubMed
31.
Zurück zum Zitat Onken C, Friesen C, et al. Safety and tolerance of D.L-methadone in combination with chemotherapy in patients with glioma. Anticancer Res. 2017;37(3):1227–36. CrossRefPubMed Onken C, Friesen C, et al. Safety and tolerance of D.L-methadone in combination with chemotherapy in patients with glioma. Anticancer Res. 2017;37(3):1227–36. CrossRefPubMed
32.
Zurück zum Zitat Salpeter SR, Buckley JS, et al. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Pall Med. 2013;16(6):616–22. CrossRef Salpeter SR, Buckley JS, et al. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Pall Med. 2013;16(6):616–22. CrossRef
33.
Zurück zum Zitat Alinejad S, Kazemi T, et al. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577–600. PubMedPubMedCentral Alinejad S, Kazemi T, et al. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577–600. PubMedPubMedCentral
34.
Zurück zum Zitat Anghelescu DL, Patel RM, et al. Methadone prolongs cardiac conduction in young patients with cancer-related pain. J Opioid Manag. 2016;12:131–8. CrossRefPubMedPubMedCentral Anghelescu DL, Patel RM, et al. Methadone prolongs cardiac conduction in young patients with cancer-related pain. J Opioid Manag. 2016;12:131–8. CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Minkowitz HS, Scranton R, et al. Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events. J Manag Care Spec Pharm. 2014;20:948–58. PubMed Minkowitz HS, Scranton R, et al. Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events. J Manag Care Spec Pharm. 2014;20:948–58. PubMed
36.
Zurück zum Zitat Christian K. Off-label use” von Arzneimitteln. In: Ennöckl D, Raschauer N, et al., editors. Über Struktur und Vielfalt im öffentlichen Recht. Vienna: Springer; 2008. Christian K. Off-label use” von Arzneimitteln. In: Ennöckl D, Raschauer N, et al., editors. Über Struktur und Vielfalt im öffentlichen Recht. Vienna: Springer; 2008.
44.
Zurück zum Zitat Krebs EE, Becker WC, et al. Comparative mortality among department of veterans affairs patients prescribed methadone or long-acting morphine for chronic pain. Pain. 2011;152:1789–95. CrossRefPubMed Krebs EE, Becker WC, et al. Comparative mortality among department of veterans affairs patients prescribed methadone or long-acting morphine for chronic pain. Pain. 2011;152:1789–95. CrossRefPubMed
45.
Zurück zum Zitat Reddy A, et al. Overall survival among cancer patients undergoing opioid rotation to methadone compared to other opioids. J Palliat Med. 2017;20(6):656–61. CrossRefPubMedPubMedCentral Reddy A, et al. Overall survival among cancer patients undergoing opioid rotation to methadone compared to other opioids. J Palliat Med. 2017;20(6):656–61. CrossRefPubMedPubMedCentral
Metadaten
Titel
Methadone as anticancer treatment: hype, hope, or hazard?
A series of case reports and a short review of the current literature and recommendations of the societies
verfasst von
Gudrun Kreye
Eva-Katharina Masel
Klaus Hackner
Beate Stich
Friedemann Nauck
Publikationsdatum
19.02.2018
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 7-8/2018
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-018-0623-5